Open Orphan #ORPH Announces New £2.5m Influenza Challenge Study Contract Win November 5, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with a US biotechnology company. The study is expected to commence at hVIVO’s 24-bedroom quarantine clinic in East London in H2…

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its acquisition by Open Orphan Plc on the 17 January 2020. Operational Highlights: · Completed the acquisition of hVIVO…

The Times – Trial to infect British volunteers with modified coronavirus at hVIVO Quarantine Centre September 29, 2020 – Posted in: Open Orphan (ORPH)

Scientists are planning to infect British volunteers with a weakened, computer-designed form of the coronavirus, which researchers believe could work as a vaccine. The early-stage trial will take place in a special 24-bed quarantine clinic in Whitechapel, east London. The US biotech company behind it, Codagenix, is in talks with UK regulators and expects to begin before the end of the year. The vaccine consists of an enfeebled version of the coronavirus, designed using special…

Open Orphan #ORPH – New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company September 28, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another of the global top 10 vaccine companies. This trial will be conducted in the Company’s dedicated human viral challenge…

Open Orphan #ORPH – Major New Contract Win with Top 3 Pharma Company August 10, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract, valued at £4m, with a top 3 global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus (RSV) human challenge study trial. This new £4m contract represents continued conversion of Open Orphan’s substantial pipeline and generation…

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial July 27, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Tuesday 28th July, 2020 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers. Highlights: First in human…

Open Orphan #ORPH – Results of Fundraising May 22, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, announces that, further to its announcement at 7.00 a.m. today (the “Fundraising Announcement”), it has successfully completed the oversubscribed Fundraising which is now closed. The Fundraising has raised approximately £12 million (net of expenses) through the placing of 109,549,098…

Open Orphan #ORPH – Proposed Fundraising to raise up to £12 million and PrimaryBid.com Offer – Posted in: Open Orphan (ORPH), Uncategorized

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, today announces its intention to raise up to £12 million (net of expenses) (the “Fundraising”) via a placing of new Ordinary Shares (“Placing Shares”) to institutional and other investors (the “Placing”), subscription of new Ordinary Shares (“Subscription Shares”) to…

Open Orphan #ORPH – Update on antibody test agreement and recent share price movement May 18, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, notes the increase in the Company’s share price and media comment regarding its collaboration with Quotient Limited. Furthermore, it also notes the substantial increase in interest in antibody testing for Covid-19 following recent announcements by the UK Government. The…

Open Orphan Chairman Cathal Friel speaks to BRR Media re the new contract, other developments and the CEO’s departure May 5, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Rosie Riall at BRR Media after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study. Cathal also covers the channel pipeline, the hVIVO quarantine centre, flu and malaria vaccines and the planned departure of CEO Trevor Phillips.